Invest in Health Security - SEPTEMBER 2020 - Amazon AWS
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Invest in Health
Security
SEPTEMBER 2020
Disclaimer This presentation (the “Presentation”) has been prepared solely for information purposes in connection with the contemplated issue of shares in ScreenPro Security Ltd. (“ScreenPro” or the “Company”) and is being furnished by ScreenPro to a limited number of parties (the “Recipients”) who have a potential interest in subscribing for shares in the Company. This presentation is being made available in the United States on a confidential basis only to persons reasonably believed to be “accredited investors” within the meaning of Rule 501(a) of Regulation D under the Securities Act (“Accredited Investors”) and specifically authorized to view this presentation. This presentation is being provided solely to enable the offeree to evaluate ScreenPro Security Ltd. (“the Company”) and the securities being offered. This information does not constitute an offer to any other person or a general offer to the public of, or the general solicitation from the public of, offers to subscribe for or purchase any of the securities in the United States. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or any other securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Purchasers of the securities in the United States will be required to be Accredited Investors. Any unauthorized use of the presentation is strictly prohibited. The material available in this presentation may contain forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward looking words such as “may”, “might”, “will”,“ should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, or “predict” and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations. Forward-looking statements are based on known and unknown risks, assumptions, uncertainties and other factors. The Company’s actual results, performance and achievements may differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company does not assume responsibility for the accuracy or completeness of any forward-looking statement and offerees should not rely on forward-looking statements as predictions of future events. The Company is under no duty to update any of these forward looking statements. The information provided in this presentation is not intended to provide financial, tax, legal or accounting advice. Each offeree, prior to investing in the Securities, should perform and rely on its own investigation and analysis of the Company and the terms of the offering of the Securities, including the merits and risks involved. Neither the receipt of this Presentation by any Recipients, nor any information contained herein or supplied herewith or subsequently communicated in written, electronic or oral form to any person in connection with the contemplated issue of shares in the Company constitutes, or shall be relied upon as constituting, the giving of investment advice to any such person. Each person should make their own independent assessment of the merits of investing in the Company and should consult their own professional advisors. By receiving this Presentation you acknowledge and agree that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and are solely responsible for forming your own opinion of the potential future performance of the Company’s business.
Index
▪ 3 Key factors for success ................................................................. 4
▪ Flow chart ................................................................. 5
▪ Key locations to test ................................................................. 6
▪ Use cases ................................................................. 7
▪ Test kit ................................................................. 8
▪ Analysis ................................................................. 9
▪ Lab partner information ................................................................. 10
▪ Financial Projections Pro Forma ................................................................. 11
▪ Company information ................................................................. 12
Management ................................................................. 13-14
Board of Directors ................................................................. 15
Advisory Board ................................................................. 16
3 KEY FACTORS FOR SUCCESS
Quality
High quality test kit
Speed Supply Chain
Fast turn around time Stable supply chain
4
FLOW CHART
Temperature Check
COVID-19 sample labeling
Specimen collection
Lab test
Result
5
KEY LOCATIONS TO TEST
Sports
tournaments School
Remote
Air
working
Traveller
locations
Film & TV
6
USE CASES
Case 1 : Case 2 : 1. Sample collecting with temperature
check for all employers & employees
Mining workplace Film & Production 2. All employers & employees receive
test result before return to work
3. Provide PPE products
Positive
• Implement quarantine measures
Negative
• Free to proceed to work
7
TEST KIT
• COVID-19 Nucleic Acid Detection Kit
• Single Molecule RNA Detection, Real-time RT-PCR
• 96 tests in 87 minutes
• Health Canada Approved ; Authorization # 312777
• FDA-EUA Approved
• ISO 13485 : 2016, ISO 14971 : 2012
• Health Canada • FDA-EUA
8
ANALYSIS
• Use RNA extraction kits and the latest PCR machine(qTOWER3 PCR)
to reduce inspection time and lead time.
• 96 or 384 wells available per PCR machine
• Convenient: Stand-alone operation via integrated tablet control (10”)
and/or comprehensive PC control
• Fast: Heating rates of 8 ℃/s, cooling rate of 6 ℃/s
Amplification curves
Dye tabs
PCR Protocols
Protocol display tabs
9
LAB PARTNER INFORMATION
Location Laboratory License
Toronto Transpharm Canada, Inc. MDEL Licence number
: 14097
Edmonton Quest Research And ISO 17025
Analytics Inc.
Vancouver CARO Analytical Services ISO 17025:2018
10FINANCIAL PROJECTIONS – PRO FORMA
$ 30,000,000
PRO FORMA
$ 25,000,000
$ 20,000,000
$ 15,000,000
$ 10,000,000
$ 5,000,000
$ 1,000,000
2020 2021 2022 2023 2024
Revenue $808,750 $5,763,000 $14,160,000 $23,400,000 $29,823,000
Net Income ($136,493) $611,340 $2,467,323 $4,559,230 $5,135,215
11
11COMPANY INFORMATION SNAPSHOT
(As of August 18th , 2020 )
▪ LOCATION: VANCOUVER
▪ SHARE OUTSTANDING : 31,000,000
▪ OPTION OUTSTANDING: N/A
▪ WARRANTS OUTSTANDING: N/A
▪ FULLY DILUTED: 31,000,000
▪ FISCAL YEAR-END: DECEMBER 31
12
12MANAGEMENT
Andrew Ryu, Chairman
Andrew Ryu is a seasoned and experienced entrepreneur and operator in public and private companies with over 20 years of
experience. Graduate of McMaster University and University of Toronto. He is the founder and CEO of TLA Inc., president of
business development of Archer Education Group and founder and former CEO of Loyalist Group Limited (TSXV: LOY), which
was nominated as the top TSXV company in 2013, ranked fourth in 2014 and was the top pick of the street in 2014. He was
nominated of EY Entrepreneur of the Year in 2014. He serves as Chairman of Graph Blockchain Inc. (CSE: GBLC) until recent.
John McMullen , CEO
John has over 20 years experience in international capital markets, focus on micro and small cap public companies and
cannabis industry thought leader and enterprise builder.
Paul Haber (CPA, CA, Cdir), CFO
Mr. Haber has been involved in corporate finance and capital markets for over 25 years as an banker, investor and
entrepreneur. He has served as the CFO and Audit Committee Chair of many public and private companies. Mr. Haber
started his career with Coopers & Lybrand, now PwC LLP. He is both a Chartered Accountant and a Certified Public
Accountant, with an Honours Bachelors of Arts Degree in Management from the University of Toronto. Mr. Haber was
awarded his Chartered Director designation from the DeGroote School of Business in partnership with the Conference
Board of Canada.
13
13MANAGEMENT
Lena Kozovski, VP Operation
Lena has worked extensively with senior executives, board members, and investors internationally, supporting their talent
management needs across a broad spectrum of areas including Senior level strategic hiring, Board and C-Suite and recruitment,
advisory services, executive assessment/succession and critical volume-based recruiting projects as well as Diversity and Inclusion
projects. Prior to establishing Element Search Partners, Ms. Kozovski held leadership roles for large global companies including CN
Rail and TD Bank. She launched her career in search 20 years ago and was most recently a Principal at a large global firm.
She holds a bachelor’s degree in human resource development from the Ryerson University in Toronto and has completed several
certificates and courses aligned with her current role. Ms. Kozovski serves as Advisor for Proudfoot, an Executive Committee
member for Women in Mining, Toronto as well as a member of Women in Mining, UK. Lena is a proponent for diversity and inclusion
within the industry and has aligned with several strategic partners to promote and advance females within the industry.
Tony Hyland, Director Sales - Film & Production
Tony has over thirty-five year career in the entertainment industry beginning in the west coast music scene. His entrepreneurial
spirit led him to from Cobra Custom Case Co. specializing in manufacturing and rental of specialized equipment for the music
industry. Today, Tony is a managing partner of Cedarwood Studios Corp. whose goal is to improve Vancouver's Studio
infrastructure. After many years of working in the various markeshif stages in Vancouver, Tony concluded there must be a more
efficient way. It is now his goal with his partners at Cedarwood Studios to build true state of the art soud stages for the growing film
industry in the Vancouver area. Tony has an extensive network of contacts in the film industry, including Studio Heads, Directors,
and Executive Producers from some of the biggest budget feature film producvers including Paramount, Disny, Netfilx, Fox,
Searchlight, Amblin Entertainment to list a few. Tony attended British Columbia Institute of Technology.
Trevor Priest, Director Sales - Transportation
Trevor Priest has over 30 years demonstrated success in sales, marketing and product development. Working with engineers and
developers to create transportation and logistics technologies that improve a fleet operator’s safety, compliance and overall
business process. A seasoned professional persistent in capturing new business has offered Trevor the opportunity to work with
some of North America’s leading technology companies including CalAmp(AirIQ, Boatracs), Trimble Technologies(PeopleNet) and
FleetOptics, ranked No.1 on Canada’s Fastest Start Up by MacLean’s magazine and The Globe and Mail, 2018.
14
14BOARD OF DIRECTORS
Young Cho Lee
Young Cho Lee (CPA) has BA in Accounting and MBA from Hanyang University in South Korea. He worked in accounting,
finance, and auditing department at LG Group- headquarter, overseeing all subsidiaries including LG Electronics, LG Construction,
and LG Chemicals. He was responsible for management and consulting projects, specializing in M&A and restructuring. After
leaving LG, he founded and operated an educational institution for 15 years in Vancouver After successful exit from education
industry, he started mobile communications and IT mobile platform businesses in Vancouver and Toronto. He has extensive
experience in management, restructuring, financial management, and sales & marketing strategy
Richard Yoon
Richard is currently the CEO of ZTE Canada responsible for ZTE’s business in Canada. Richard joined ZTE Canada in April, 2015 as
Director of Business Development, with responsibilities for developing new business opportunities in Canada. Within short time
frame, Richard made significant contribution to the business growth in Canada and now serves as CEO of ZTE Canada. Richard is a
strategic thinker, team-oriented and results driven leader with a track record of innovation and success in the business world. Prior
to joining ZTE Canada, Richard has worked in management positions for several other OEM such as Huawei and Palm and has also
held management positions with Canadian Telecom carriers such as TELUS, Bell and Clearnet. Richard holds a Bachelors degree in
Mathematics for commerce from York University.
Jeff Stevens
Mr. Stevens was the CEO Graph Blockchain (CSE:GBLC), a private blockchain solutions company. He is the Advisory Board Member of
Datametrex AI Ltd. (TSXV:DM), an Artificial Intelligence and Machine Learning company, and a Director at New Wave Holdings, a
private eSports and eGaming Investment Company.
In addition to Mr. Stevens experience as an operator, he also brings 20 + years of professional experience in the Canadian Capital
Markets. Through the course of his career he was the head of two Sales and Trading desks and was instrumental in building the
Canadian operations for a US based Investment Bank in Toronto. Jeff's experience was largely focused on capital raising for micro
cap and small cap companies in Canada. His client base included Institutional Money Managers, Hedge Funds, Mutual Funds and
Family Offices in Canada, US and Europe.
15
15ADVISORY BOARD
Marshall Gunter
Mr. Gunter’s engineering background is rooted in big data analysis and machine learning at scale. Working with Sequoia
Capital and Lightspeed Venture Partners, Marshall was responsible for bringing Varagesale to the mass market. Marshall
took Varagesale from a one room shop to a powerhouse engineering department of 60 plus people and played a leading
role in their $35-million-dollar raise. Marshall lead the team that built iSentium’s sentiment engine. iSentium uses
patented Natural Language Processing (NLP) to extract sentiment from unstructured social content then instantly
transforms it into highly actionable indicators in finance, brand management and politics, handling billions of data points
to harness the power of the masses as they tweet and text.
Alexander MacGregor, Ph.D.
Dr. Alexander MacGregor is a leader in the fields of pharmaceutical technology, research, and training, He has served as the President and Dean
of Faculty of the Toronto Institute of Pharmaceutical Technology (TIPT) since 1992. He obtained his Ph.D. in clinical pharmacology from the
University of London Postgraduate Medical School after earning honors in medical biochemistry from the University of Wales. In 1997, He
completed a Master-Class Certification Program in Pharmaceutical Technology from the European Continuing Education College at the University
of Liverpool. Throughout the decade, He functioned as a consultant to major pharmaceutical industries in Europe, Asia, and North America. He
currently divides his time between TIFT, one of North America's leading postgraduate pharmaceutical and research organizations, and ORx
Pharmaceutical Corporation, where he serves as chairman and Chief Scientific Officer. In the latter capacity, He designs and develops clinical
delivery methods of therapeutic compounds. At TIPT, He runs a highly regarded training program in pharmaceutical sciences and technology.
More than 2,600 successful TIPT graduates operate in all areas of the pharmaceutical industry including quality control analysis, regulatory affairs
administration, clinical quality control, and clinical data review. The holder of several scientific patents, He currently oversees clinical testing
trials of several drugs in the areas of cholesterol lowering, diabetes, anti-infective, post-operative pain, epilepsy, and congestive heart failure.
Dr. David Klein, MD
Dr. David Klein currently works in conjunction with Dr. Alexander Romaschin in the Department of Laboratory
Medicine at St. Michael’s Hospital on the development and clinical application of novel biomarkers to acute
care and critical care. I am also involved in the development of novel therapeutics targeting endotoxin in
critical illness, as well as the linkage of diagnostics and therapeutics. Separately, I lead business strategy and
partnerships for the Applied Health Research Centre (AHRC) and hold advisory roles to government and
other policy makers regarding the healthcare system and business strategy.
16
16Contact
We value our investors - Please contact us via your preferred method if you have any questions:
Jamie Hyland, President & CEO
jhyland@screenprosecurity.com
(604) 442-2425
625 Howe Street, Suite 260
Vancouver, BC, V6C 2T6You can also read
